Unlike A/I degraders, including thalidomide and pomalidomide, lenalidomide has a CK1α-degrading effect (5, 9) and has been used to treat several hematopoietic malignancies, including DLBCL, follicular lymphoma (FL), MCL, and 5q deletion myelodysplastic syndrome [del(5q) MDS] (4, 5, 9). The gene discussed is CSNK1A1; the disease is myelodysplastic syndrome.